257 related articles for article (PubMed ID: 19744802)
21. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
[TBL] [Abstract][Full Text] [Related]
23. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
[TBL] [Abstract][Full Text] [Related]
24. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
26. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
28. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
30. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
32. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
33. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
36. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
39. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
40. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
